Use of pentacyclic triterpenoid structure-modified compound in preparation of vitiligo medicament, and new formulation

Through the five-ring triterpene structural modification compound CKBA, the differentiation of CD8+ T cells, especially the Tc1 and Tc17 subgroups, it solves the problems of poor targeted and large side effects of existing vitiligo treatment methods, significantly improves the symptoms of vitiligo, and provides a new Treatment pathway.

WO2024230460A1PCT designated stage expired Publication Date: 2024-11-14SUZHOU BOTANY BIOMEDICALS
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/089042
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-11-02
Filing Date
2024-04-22
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

The existing treatment methods for vitiligo lack effective drugs. Commonly used drugs are poorly targeted to the disease and have serious side effects, resulting in poor treatment effects and lack of new drug development in the market, resulting in slow market dynamic changes.

Method used

Using pentacyclic triterpene structural modification compounds, especially 3-o-α-cyclohexanoyl-11-keto-β-boswellic acid (CKBA), as the active ingredient for the preparation of vitiligo drugs, by inhibiting the differentiation of CD8+ T cells, especially The Tc1 and Tc17 subgroups are used to relieve or treat vitiligo, and are optimized to form ointment preparations to improve skin absorption.

Benefits of technology

CKBA significantly reduces the differentiation efficiency of CD8+ T cells, reduces the production of IFN-γ and IL-17A, improves the skin phenotype of animal models of vitiligo, reduces CD8+ T cell infiltration, and significantly improves the symptoms of vitiligo, providing a new treatment Drug routes for vitiligo.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTCN2024089042-FTAPPB-I100001
    Figure PCTCN2024089042-FTAPPB-I100001
  • Figure PCTCN2024089042-FTAPPB-I100002
    Figure PCTCN2024089042-FTAPPB-I100002
  • Figure PCTCN2024089042-FTAPPB-I100003
    Figure PCTCN2024089042-FTAPPB-I100003
Patent Text Reader

Abstract

The present invention relates to a use of a pentacyclic triterpenoid structure-modified compound in preparation of a vitiligo medicament, and a new formulation. Specifically, the present invention relates to a pentacyclic triterpenoid structure-modified compound capable of effectively treating vitiligo. The pentacyclic triterpenoid structure-modified compound can also be used for inhibiting differentiation of CD8+T cells, and particularly inhibiting differentiation of the CD8+T cells into a Tc1 cell subset and / or a Tc17 cell subset. The present invention provides a new way for alleviation and treatment of vitiligo, and also provides a new way for differentiation regulation and control of the CD8+T cells to different subsets. The present invention also optimizes the formulation of the pentacyclic triterpenoid structure-modified compound, and provides an ointment formulation having an excellent effect, which contains a series of adjuvants and can assist the pentacyclic triterpenoid structure-modified compound in being better absorbed by a skin.
Need to check novelty before this filing date? Find Prior Art

Description

Application of pentacyclic triterpenoid structure-modified compounds in the preparation of vitiligo drugs and new preparations

[0001] This application claims priority to the patent application filed on May 10, 2023 with application number CN202310524579.0; and claims priority to the patent application filed on November 2, 2023 with application number CN202311448294.X; all contents of which are incorporated herein. Technical Field

[0002] The present invention belongs to the field of medicine, and more specifically, relates to the application of pentacyclic triterpene structure-modified compounds in the preparation of vitiligo drugs and new preparations. Background Art

[0003] Vitiligo, commonly known as "white spots" and "white spots", is a common acquired localized or generalized skin disease with typical skin lesions of varying sizes and numbers of depigmented spots, which generally have no subjective symptoms.

[0004] The incidence of vitiligo in the world's population is 0.5% to 1%. It is reported that the incidence of vitiligo varies depending on race, geographical environment, and population (Ezzedine K, et al., 2015, 386(9988): 74-84). Currently, the prevalence of vitiligo is showing an increasing trend year by year.

[0005] Based on the Vitiligo Global Issue Consensus Conference and current mainstream views at home and abroad, the Chinese Vitiligo Diagnosis and Treatment Consensus (2018 Edition) divides vitiligo into four types: common, segmental, mixed, and undetermined. The term "vitiligo" usually refers to vitiligo vulgaris, also known as non-segmental vitiligo (NSV) (Meredith F, et al., 2013, 170(3): 565-70).

[0006] Vitiligo is divided into progressive stage and stable stage according to whether the condition progresses: in progressive stage, the condition of patients progresses, and the area of ​​white spots tends to expand in the near future; in stable stage, the condition of patients is stable, and the area of ​​white spots shrinks or remains unchanged.

[0007] The pathogenesis of vitiligo remains unknown, and it is difficult to treat and recurs repeatedly. While it does not affect physical health, it places a significant psychological burden on patients, severely impacting their quality of life and easily leading to various psychological symptoms or illnesses. Therefore, vitiligo is a major research topic in the field of skin diseases worldwide.

[0008] Although vitiligo is considered immune-related, it is a unique disease with a distinct pathogenesis and symptoms. While it manifests as changes on the skin surface, it is distinct from, for example, psoriasis. Some theories suggest that when immune function is disrupted, the immune system attacks melanocytes, leading to apoptosis, decreased tyrosinase activity, and reduced melanin content, resulting in white spots. However, the underlying mechanisms remain unclear. Genome-wide association studies (GWAS) and functional pathway analyses (SHEN C, et al., 2016, 7:3) have revealed that most vitiligo susceptibility loci encode immunomodulatory proteins or melanocyte components that mediate immune targeting.

[0009] To date, there are no new drugs for vitiligo worldwide, and several JAK-STAT inhibitors are in clinical trials. According to the Vitiligo Research Foundation's 2021 New Drug Progress Report (Vitiligo Drug Pipeline Analysis and Market Insights-UPDATE), as of 2018, the global vitiligo treatment market was US$143.8 million and is expected to reach US$144.5 million by 2026, with a compound annual growth rate of 5.8%. The largest market share (54.7%) is for topical drugs, the second largest share is phototherapy, followed by surgical methods and others. The dynamics of the vitiligo market are expected to change rapidly in the next 3 to 7 years, because developing new vitiligo drugs from scratch may take a long time (ten years), but using drugs that have been approved to treat other diseases, such as JAK inhibitors, can launch drugs the fastest, but the production cost is high and the price is expensive.

[0010] Currently, the main topical drugs used in clinical treatment of vitiligo include glucocorticoids, calcium-phosphate inhibitors, etc., which are actually not very effective against vitiligo and have poor targeting, and can easily lead to serious adverse reactions and side effects.

[0011] Therefore, there is an urgent need to find new drugs for treating vitiligo in this field, in order to change the current situation that vitiligo has no cure or the treatment effect is unsatisfactory.

[0012] Summary of the Invention

[0013] The purpose of the present invention is to provide the use of a pentacyclic triterpene structure-modified compound in the preparation of vitiligo medicines and a new preparation.

[0014] The present invention also aims to provide a novel use of a pentacyclic triterpene structure-modified compound, which is to inhibit CD8 + T cell differentiation; in particular, inhibiting its differentiation into Tc1 subset and / or Tc17 subset.

[0015] In a first aspect of the present invention, there is provided the use of a compound represented by formula (I) or its isomers, solvates or precursors, or pharmaceutically acceptable salts thereof, for preparing a pharmaceutical composition for alleviating or treating vitiligo;

[0016] Wherein, R is independently selected from the group consisting of hydrogen, hydroxy, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, and halogen.

[0017] In one or more embodiments, the pharmaceutical composition containing the compound represented by formula (I) is an external dosage form.

[0018] In one or more embodiments, the pharmaceutical composition containing the compound of formula (I) is selected from: ointments (such as creams, pastes), gels, foams, sprays, powders, and creams.

[0019] In one or more embodiments, the pharmaceutical composition is an ointment preparation, comprising: a compound represented by formula (I); and:

[0020] Adjuvant 1 is selected from one or more of white vaseline, paraffin, lanolin, microcrystalline wax, beeswax, spermaceti, ozokerite, glyceryl stearate, stearic acid, or cholesterol; preferably, the paraffin is light liquid paraffin; preferably, the adjuvant 1 is white vaseline and light liquid paraffin;

[0021] Adjuvant 2 is selected from one or more of isopropyl myristate, azone or N-methylpyrrolidone; preferably, the adjuvant 2 is isopropyl myristate;

[0022] The auxiliary agent 3 is selected from one or more of vitamin E, butylated hydroxytoluene, butylated hydroxyanisole, tocopherol, propyl gallate or tert-butylhydroquinone; preferably, the auxiliary agent 3 is vitamin E.

[0023] In one or more embodiments, the vitiligo is: CD8 + Vitiligo is caused by the differentiation of T cells into Tc1 cell subsets (effector cells that produce IFN-γ).

[0024] In one or more embodiments, the vitiligo is: CD8 + Vitiligo is caused by T cell differentiation into Tc17 cell subsets (effector cells that produce IL-17A).

[0025] In one or more embodiments, the compound represented by formula (I) has a structure represented by formula (II).

[0026] The English name of the compound of formula (II) is 3-o-α-cyclohexanoyl-11-keto-β-boswellic acid, abbreviated as CKBA.

[0027] In another aspect of the present invention, a pharmaceutical composition for alleviating or treating vitiligo comprises: a compound represented by formula (I); and:

[0028] Adjuvant 1 is selected from one or more of white vaseline, paraffin, lanolin, microcrystalline wax, beeswax, spermaceti, ozokerite, glyceryl stearate, stearic acid or cholesterol; preferably, the paraffin is light liquid paraffin; preferably, the adjuvant 1 is white vaseline and light liquid paraffin;

[0029] Adjuvant 2 is selected from one or more of isopropyl myristate, azone or N-methylpyrrolidone; preferably, the adjuvant 2 is isopropyl myristate; and

[0030] The auxiliary agent 3 is selected from one or more of vitamin E, butylated hydroxytoluene, butylated hydroxyanisole, tocopherol, propyl gallate or tert-butylhydroquinone; preferably, the auxiliary agent 3 is vitamin E.

[0031] In one or more embodiments, the pharmaceutical composition comprises: a compound represented by formula (I), white vaseline, light liquid paraffin, isopropyl myristate, and vitamin E, in parts by weight:

[0032] The compound represented by formula (I): 25-250, preferably 50-200, such as 65, 75, 90, 120, 150 or 180 parts by weight; white petrolatum: 9000-18000, preferably 10000-16500, such as 12000, 13347, 13422 or 15000 parts by weight; light liquid paraffin: 400-1200, preferably 550-1000, such as 600, 650, 750, 800 or 900 parts by weight; isopropyl myristate: 400-1200, preferably 550-1000, such as 600, 650, 750, 800 or 900 parts by weight; vitamin E: 1.5-5, preferably 2-4.5, such as 2.5, 3 or 4 parts by weight.

[0033] In another aspect of the present invention, there is provided a use of a compound represented by formula (I) or its isomers, solvates or precursors, or pharmaceutically acceptable salts thereof, for preparing a method for inhibiting CD8 + Compositions for T cell differentiation (such as cell culture media or pharmaceutical compositions);

[0034] In one or more embodiments, the inhibition of CD8 + T cells differentiate into:

[0035] Suppression of CD8 + Differentiation of T cells into Tc1; and / or

[0036] Suppression of CD8 + Differentiation of T cells into Tc17.

[0037] In one or more embodiments, the compound of formula (I) is prepared by the following method: using 11-carbonyl-β-acetylboswellic acid as a raw material, replacing the AcO- group with group.

[0038] In one or more embodiments, the compound of formula (I) is prepared by the following method:

[0039] (i) using 11-carbonyl-β-acetylboswellic acid as a raw material and reacting it with a base to obtain 11-carbonyl-β-boswellic acid; and

[0040] (ii) reacting 11-carbonyl-β-boswellic acid with cyclohexanecarbonyl chloride to obtain a compound represented by formula (I).

[0041] In one or more embodiments, the compound represented by formula (I) or its isomer, solvate or precursor, or pharmaceutically acceptable salt thereof is used as the main active ingredient (active component) in the composition (including pharmaceutical composition).

[0042] In one or more embodiments, the compound represented by formula (I) or its isomer, solvate or precursor, or pharmaceutically acceptable salt thereof is used as the sole active ingredient (active component) in the composition (including pharmaceutical composition).

[0043] In one or more embodiments, the compound represented by formula (I) or its isomers, solvates or precursors, or pharmaceutically acceptable salts thereof can be used in combination with other active ingredients, each of which exerts an independent effect.

[0044] In one or more embodiments, the compound represented by formula (I) or its isomers, solvates or precursors, or pharmaceutically acceptable salts thereof can be used in combination with the adjuvant (preferably white petrolatum, light liquid paraffin, isopropyl myristate and vitamin E) to exert a synergistic effect.

[0045] In another aspect of the present invention, a method for inhibiting CD8 + The method for differentiating T cells comprises: treating CD8 T cells with a compound represented by formula (I) or its isomer, solvate or precursor, or a pharmaceutically acceptable salt thereof; + T cells, thereby inhibiting CD8 + Differentiation of T cells.

[0046] In one or more embodiments, the inhibition of CD8 + T cell differentiation: suppressor CD8 + T cells differentiate into the Tc1 subset (which suppresses the production of IFN-γ-producing effector cells).

[0047] In one or more embodiments, inhibition of CD8 + T cells differentiate into the Tc17 subset (which suppresses the generation of IL-17A-producing effector cells).

[0048] In one or more embodiments, the compound of formula (I) or its isomer, solvate or precursor, or a pharmaceutically acceptable salt thereof is in CD8 + The concentration in T cell culture is 1-100 uM; preferably 2-80 uM (such as 3, 4, 5, 6, 8, 10, 12, 15, 20, 30, 40, 50, 60 or 70 uM, etc.).

[0049] In one or more embodiments, the method maintains CD8 + T cells are in an undifferentiated state.

[0050] In one or more embodiments, the method maintains CD8 + Naive CD8 T cells + T cells.

[0051] In one or more embodiments, the inhibition of CD8 + The T cell method is an in vitro method.

[0052] In one or more embodiments, the inhibition of CD8 + T cell method is to inhibit CD8 + T cell culture / cell population (eg, enriched cell population or passaged cell population).

[0053] In one or more embodiments, the inhibition of CD8 + The T cell method is a method that does not directly aim to treat a disease (a non-therapeutic method).

[0054] In another aspect of the present invention, a method for alleviating or treating vitiligo is provided, comprising: administering an effective amount of the pharmaceutical composition of the present invention to a subject in need of treatment.

[0055] Other aspects of the present invention will be apparent to those skilled in the art in view of the disclosure herein. BRIEF DESCRIPTION OF THE DRAWINGS

[0056] Figure 1A, Figure 1B and Figure 1C: CKBA compounds reduce CD8+ It also induces the differentiation efficiency of T cells into Tc1 and inhibits the production of IFN-γ.

[0057] Figure 2A, Figure 2B and Figure 2C: CKBA compounds reduce CD8 + It induces the differentiation efficiency of T cells into Tc17 and inhibits the production of IL-17A.

[0058] Figure 3: CKBA ointment treats vitiligo animal models, effectively improving the vitiligo phenotype (the degree of hair whitening) of the animals, with blank ointment serving as a control.

[0059] Figure 4: CKBA ointment treats vitiligo animal models, resulting in CD8 infiltration in the animal skin. + The infiltration of T cells was significantly reduced. DETAILED DESCRIPTION

[0060] After in-depth research, the inventors have revealed for the first time that a pentacyclic triterpene structure-modified compound can effectively treat vitiligo. In order to improve the efficacy, the present invention also optimizes the preparation of the pentacyclic triterpene structure-modified compound and provides an ointment preparation with excellent effect containing a series of adjuvants, which can help the pentacyclic triterpene structure-modified compound be better absorbed by the skin. The pentacyclic triterpene structure-modified compound can also be used to inhibit CD8 + The present invention was completed on this basis.

[0061] the term

[0062] The term "alkyl" as used herein refers to a straight or branched saturated aliphatic hydrocarbon group containing 1 to 4 carbon atoms (preferably 1 to 2 carbon atoms). For example, alkyl includes but is not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, and tert-butyl.

[0063] As used herein, the term "alkenyl" includes straight and branched chain hydrocarbon groups containing at least one carbon-carbon double bond and 2 to 4 carbon atoms, preferably 2 to 3 carbon atoms.

[0064] As used herein, the term "alkynyl" includes straight and branched chain hydrocarbon groups containing at least one carbon-carbon triple bond and 2 to 4 carbon atoms, preferably 2 to 3 carbon atoms.

[0065] The term "halogen" as used herein refers to F, Cl, Br, or I.

[0066] The term "isomer" as used herein includes geometric isomers, enantiomers, diastereomers (eg, cis-trans isomers, conformational isomers).

[0067] The ones used in this article The representation of is well known to those skilled in the art, and indicates that the group R can be substituted at any one or more substitutable positions on the ring. Furthermore, the choice of R can be different at different substitution positions.

[0068] The term "solvate" used herein refers to a compound that carries solvent molecules, for example, the solvate may be a hydrate.

[0069] In the present invention, the term "comprising" means that various components can be used together in the mixture or composition of the present invention. Therefore, the terms "consisting mainly of" and "consisting of" are included in the term "comprising".

[0070] In the present invention, a "pharmaceutically acceptable" ingredient is a substance that is suitable for use in humans and / or animals without excessive adverse side effects (such as toxicity, irritation, and allergic reactions), that is, with a reasonable benefit / risk ratio.

[0071] In the present invention, the pharmaceutical composition may further include a "pharmaceutically acceptable carrier," which is a pharmaceutically or food-acceptable solvent, suspending agent, or excipient for delivering the compound of formula (I), isomer, solvate, precursor, or pharmaceutically acceptable salt thereof to animals or humans. The carrier may be a liquid or a solid.

[0072] In the present invention, unless otherwise specified, the "culture medium" is suitable for CD8 + T cell growth medium, in which some factors can be added to make CD8 + T cells differentiate (simulating CD8 + T cell differentiation process). For example, adding anti-CD3, anti-CD28, IL-2 and IL-12 causes the cells to differentiate into effector cells that produce IFN-γ, referred to as Tc1 cells. For example, adding anti-CD3, anti-CD28, TGF-β, IL-6, IL-23, IL-1β and anti-IFN-γ causes the cells to differentiate into effector cells that produce IL-17A, referred to as Tc17 cells (this simulates the CD8 in vivo environment). + T cells differentiate into Tc17).

[0073] As used in the present invention, the "CD8 + "Vitiligo caused by T cell differentiation into Tc1 cell subsets (effector cells that produce IFN-γ)" refers to a type of vitiligo that is mainly caused by excessive production of IFN-γ.

[0074] As used in the present invention, the "CD8 +"Vitiligo caused by T cell differentiation into Tc17 cell subsets (effector cells that produce IL-17A)" refers to a type of vitiligo that is mainly caused by excessive production of IL-17A.

[0075] Compound

[0076] The present invention first provides a compound as shown in structural formula (I):

[0077] Wherein, R is independently selected from the group consisting of hydrogen, hydroxy, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, and halogen. Preferably, R is independently selected from the group consisting of hydrogen, hydroxy, and C1-C2 alkyl.

[0078] The present invention also includes isomers, solvates, precursors, or pharmaceutically acceptable salts thereof of the compound of formula (I), as long as they also have the same or substantially the same function as the compound of formula (I). The "pharmaceutically acceptable salt" refers to a salt formed by the reaction of a compound with an inorganic acid, an organic acid, an alkali metal or an alkaline earth metal. These salts include (but are not limited to): (1) salts formed with the following inorganic acids: such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid; (2) salts formed with the following organic acids: such as acetic acid, oxalic acid, succinic acid, tartaric acid, methanesulfonic acid, maleic acid, or arginine. Other salts include salts formed with alkali metals or alkaline earth metals (such as sodium, potassium, calcium or magnesium) in the form of esters, carbamates, or other conventional "prodrugs". The compounds have one or more asymmetric centers. Therefore, these compounds may exist as racemic mixtures, individual enantiomers, individual diastereomers, diastereomeric mixtures, cis or trans isomers.

[0079] The "precursor of the compound" refers to a compound that undergoes metabolism or chemical reactions in the patient's body after being taken by an appropriate method and is converted into a compound of structural formula (I), or a salt or solution composed of a compound of chemical structural formula (I).

[0080] As a preferred embodiment of the present invention, the compound has a structure shown in formula (II).

[0081] The English name of the compound of formula (II) is 3-o-α-cyclohexanoyl-11-keto-β-boswellic acid, abbreviated as CKBA. Its molecular formula is C 37 H 56 O5, molecular weight 581.

[0082] Those skilled in the art will understand that, after knowing the structure of the compound of the present invention, the compound of the present invention can be obtained by a variety of methods well known in the art using known raw materials, such as chemical synthesis or extraction from organisms (such as animals or plants), and these methods are all included in the present invention.

[0083] For example, as a method for preparing the compound represented by formula (I) of the present invention, the method comprises: using 11-carbonyl-β-acetylboswellic acid as a raw material, replacing the AcO- group thereof with Group. More preferably, the preparation steps include: (i) reacting 11-carbonyl-β-acetylboswellic acid (AKBA) with a base (such as KOH) to obtain 11-carbonyl-β-boswellic acid; and (ii) reacting 11-carbonyl-β-boswellic acid with cyclohexanecarbonyl chloride to obtain the compound represented by formula (I). Other methods for preparing the compound represented by formula (I) are also included in the present invention. For example, 11-carbonyl-β-boswellic acid (KBA) can be used as a raw material and reacted with cyclohexanecarbonyl chloride to directly obtain the compound represented by formula (I).

[0084] The synthesized compound can be further purified by column chromatography, high performance liquid chromatography, etc. In addition, it can also be further purified by crystallization. It should be understood that a variety of purification methods can be applied to the present invention.

[0085] Uses: Relieve or treat vitiligo

[0086] 11-Carboxy-β-acetylboswellic acid, also known as acetyl-11-keto-β-boswellic acid (AKBA), is a key component of the gum resin of the plant Boswellia carlesii. Frankincense extracts have been used in traditional medicine as anti-inflammatory agents, such as for the treatment of arthritis and ulcerative colitis. Boswellic acid has also garnered attention for its antiproliferative effects, inhibiting the growth and apoptosis of several leukemia and melanoma cell lines in vitro. Studies on boswellic acids have shown that 11-carboxy-β-acetylboswellic acid exhibits the most significant 5-LOX inhibitory activity (British J Pharmacology, 1996, 117, 615-618).

[0087] In previous work, the inventors chemically modified AKBA to create a novel compound, 3-o-α-cyclohexanoyl-11-keto-β-boswellic acid (CKBA). Compared to AKBA, CKBA significantly inhibited cell division and proliferation and exhibited a more pronounced therapeutic effect in a mouse model of psoriasis. However, the efficacy of either AKBA or CKBA for vitiligo, a condition whose mechanism of action is quite different from that of psoriasis, remained unclear.

[0088] The present invention clearly discloses for the first time that the compound represented by structural formula (I) has the function of alleviating or treating vitiligo, and the technical effect is excellent. Vitiligo is a special disease that has very significant differences in pathogenesis and symptoms from other types of skin diseases such as psoriasis.

[0089] Through studies at the cellular level and animal disease models, the present inventors have demonstrated that CKBA has significant uses in treating vitiligo.

[0090] Based on the inventors' novel discoveries, the present invention discloses a novel use for a pentacyclic triterpene structure-modified compound. A preferred compound of the present invention is acetyl-11-keto-β-boswellic acid (AKBA), a chemically modified compound with enhanced biological activity: 3-O-α-cyclohexanoyl-11-keto-β-boswellic acid (CKBA). In vivo experiments have shown that CKBA effectively improves the vitiligo phenotype in mice. It can be used to prepare a drug for the treatment and / or prevention of vitiligo.

[0091] The present invention discloses a novel medical use of a CKBA compound or an analog thereof (i.e., a compound of formula (I) of the present invention, or an isomer, solvate, or precursor thereof, or a pharmaceutically acceptable salt thereof), namely, use thereof in the preparation of a medicament for treating and / or preventing vitiligo. Furthermore, the present invention also includes a medicament for treating vitiligo, wherein the active ingredient is CKBA or an analog thereof.

[0092] The CKBA compound or its analogue described herein is formulated into a topical dosage form using conventional pharmaceutical preparations and pharmaceutically acceptable excipients. Preferably, the weight content of the CKBA compound or its derivative can be 0.01% to 1.5%. It should be understood that physicians may also vary the dosage appropriately based on clinical circumstances.

[0093] The present invention also provides a method for alleviating or treating vitiligo, comprising administering an effective amount of the compound represented by formula (I) or its isomers, solvates or precursors, or pharmaceutically acceptable salts thereof to a subject in need of treatment.

[0094] Purpose: Regulate CD8 + T cell differentiation

[0095] In cytotoxic T lymphocytes (CTL), CD8 + T cells belong to a subpopulation that expresses CD8 on their surface. CD8 is a dimeric co-receptor that allows CD8 +T cells recognize peptides presented by MHC class I proteins.

[0096] Naive CD8 differentiated into effector or memory cell types + T cells play a specific role in mediating adaptive immune responses. + T cells can differentiate into a variety of subpopulations, each with distinct functions and roles. + T cell subtypes include Tc1, Tc2, Tc9, Tc17, Tc22, etc.

[0097] The present inventors found that CKBA can effectively reduce CD8 + The in vitro differentiation efficiency of T cells into Tc1 and Tc17 was improved, and the production of IFN-γ and IL-17A was reduced.

[0098] CD8 + T cells can mediate the killing effect of melanocytes. CD8 + The T cell content was significantly increased, and the severity of the disease and the ability to kill melanocytes were significantly related to CD8 + There was a positive correlation between the number of T cells and the expression of interferon-γ (IFN-γ) and interleukin-17A (IL-17A) in serum. + T cells are an important target.

[0099] The present invention aims at the pathogenesis of vitiligo and adopts relevant pharmacological experimental methods to conduct in vitro and in vivo efficacy experiments on CKBA compounds for the treatment of vitiligo. + T cell division and proliferation, in vitro differentiation efficiency, cytokine production capacity, degree of re-pigmentation of depigmented skin, skin CD8 + The efficacy of CKBA compounds in the treatment of vitiligo was studied by T cell infiltration and other aspects.

[0100] In the embodiment of the present invention, the experiment shows that the use of CKBA compound can effectively reduce the naive CD8 + In vitro induction and differentiation efficiency of T cells, inhibition of IFN-γ and IL-17A production; can help the skin or hair of vitiligo mouse models to recolor, reduce the number of CD8 + T cell infiltration improves the vitiligo-like phenotype in mice.

[0101] Based on the new discovery of the present inventors, the present invention also provides the use of the compound represented by formula (I) or its isomers, solvates or precursors, or pharmaceutically acceptable salts thereof, for preparing a method for inhibiting CD8 +The composition can be a cell culture medium or a pharmaceutical composition. + T cell differentiation: suppressor CD8 + T cell differentiation into the Tc1 subset (inhibiting the generation of IFN-γ-producing effector cells); and / or suppressing CD8 + T cells differentiate into the Tc17 subset, which suppresses the production of IL-17A-producing effector cells.

[0102] Once stimulated by cytokines (such as IL-2 and IL-12), the Tc1 cell subset has the ability to kill target cells directly or indirectly. In addition, cytotoxic Tc1 cells can release IFN-γ or TNF-α to further regulate the host's immune response. Tc2 T cells regulate effector and auxiliary immune responses by secreting cytokines IL-4, IL-5, IL-10, and IL-13. Although Tc2 cells have the ability to perform cytotoxic functions, this T cell subset is generally not as effective as its Tc1 counterpart during infection.

[0103] The Tc17 cell subset is distinct from the Tc1 subset. It is an IL-17+-secreting CD8+ effector cell and represents a novel cell subset independent of both cellular function and differentiation. Tc17 cells possess a completely different phenotype from other cytotoxic T cells, secreting little or no IFN-γ and IL-4. Compared to Tc1 and Tc2 cells, Tc17 cells express neither granzyme B nor perforin, and lack cytotoxic activity against antigen-bound targets. Compared to Th17 cells, Tc17 cells are significantly different. Tc17 cells have been shown to function in a variety of conditions and are associated with a higher proportion of neutrophils in the lungs compared to animals injected with Tc1. Tc17 cells have also been shown to participate in immune responses in several diseases, thereby modulating disease states. Therefore, developing methods to regulate Tc17 is necessary.

[0104] The present invention discloses for the first time that the compound represented by formula (I) or its isomers, solvates or precursors, or their pharmaceutically acceptable salts have the ability to regulate CD8 + The ability of T cells to differentiate into Tc1 or Tc17 subsets provides an effective way to regulate the differentiation of such cell subsets.

[0105] Composition

[0106] The pharmaceutical compositions of the present invention may be formulated in a variety of dosage forms, as long as they allow the active ingredients to effectively reach the mammalian body. For example, they may be selected from the group consisting of gels, aerosols, tablets, capsules, powders, granules, syrups, solutions, and suspensions. Depending on the disease to be treated by the compounds of the present invention, those skilled in the art will be able to select a dosage form that is convenient for use.

[0107] From the standpoint of ease of preparation and administration, preferred pharmaceutical compositions are solid or semi-solid compositions. The compounds of the present invention or their pharmaceutical compositions can also be stored in sterile devices suitable for injection or infusion.

[0108] When used to alleviate or treat vitiligo, it is preferred that the pharmaceutical composition be administered in an external manner. Various pharmaceutical carriers suitable for preparing external dosage forms can be applied to the present invention. As a preferred embodiment of the present invention, the pharmaceutical composition containing the compound shown in formula (I) is an external dosage form, including (but not limited to) selected from: ointments (such as creams, pastes), gels, foams, sprays, powders, creams.

[0109] As a preferred embodiment of the present invention, a pharmaceutical composition for treating vitiligo is provided, comprising: (a) an effective amount of a compound of formula (I), or an isomer, solvate, precursor, or pharmaceutically acceptable salt thereof; and (b) an adjuvant. The adjuvant is suitable and can synergize and enhance the therapeutic effect of the compound of formula (I). The adjuvant includes: adjuvant 1, selected from: one or more of white vaseline, paraffin, lanolin, microcrystalline wax, beeswax, spermaceti, ozokerite, glyceryl stearate, stearic acid, or cholesterol; adjuvant 2, selected from: one or more of isopropyl myristate, azone, or N-methylpyrrolidone; adjuvant 3, selected from: one or more of vitamin E, butylated hydroxytoluene, butylated hydroxyanisole, tocopherol, propyl gallate, or tert-butylhydroquinone.

[0110] Most preferably, the adjuvants include: white petrolatum, light liquid paraffin, isopropyl myristate and vitamin E.

[0111] The effective dosage of the compound of formula (I) as the active ingredient may vary with the mode of administration and the severity of the disease to be treated. For example, a compound of the present invention may be administered daily at a dose of about 0.0001-500 mg / kg, preferably 0.001-300 mg / kg, more preferably 0.01-200 mg / kg of animal body weight, with satisfactory results, preferably in 1-3 divided doses per day, or in a sustained-release form. This dosage regimen may be adjusted to provide the optimal therapeutic response. For example, depending on the urgency of the treatment condition, several divided doses may be administered daily, or the dosage may be reduced proportionally.

[0112] In addition, the compound of formula (I), or its isomers, solvates, precursors, or pharmaceutically acceptable salts thereof, can also be added to an appropriate culture medium for regulating CD8+ T cell differentiation. In some preferred embodiments, the concentration of the compound in the culture medium is 1 to 100 μM, preferably 2 to 80 μM. This addition amount can be adjusted according to actual conditions.

[0113] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended to illustrate the present invention only and are not intended to limit the scope of the invention. The experimental methods in the following examples, for which specific conditions are not specified, are generally carried out under conventional conditions or under conditions recommended by the manufacturer.

[0114] Example 1: In vitro inhibition of CD8+ T cell differentiation into Te1 by CKBA compounds

[0115] 8-10 week old C57BL / 6 mice were selected and erythrocytes were lysed with erythrocyte lysis buffer to obtain spleen single cell suspension. + Naive CD8 T cells were isolated by magnetic bead enrichment kit. + T cells. 1.0*10 per well 5 The cells were seeded in 96-well plates and differentiated into IFN-γ-producing effector cells, referred to as Tc1 cells, under the induction conditions of anti-CD3, anti-CD28, IL-2 and IL-12.

[0116] To the cells prepared above, a gradient of CKBA compounds (dissolved in DMSO, with a DMSO-free control group serving as a control) was added. The total volume was 200 μl / well. The control group received the corresponding concentration of DMSO, while the blank control group received only 200 μl of culture medium. Three replicate wells were set up for each group.

[0117] After culturing in a cell culture incubator (37° C., 5% CO 2 ) for 72 hours, the proportion of Tc1 cells was detected by flow cytometry.

[0118] As shown in Figures 1A-C and Table 1, the results show that CKBA compounds can effectively reduce the in vitro differentiation efficiency of Tc1 cells. Compared with the DMSO control group, CKBA significantly inhibited the differentiation of Tc1 cell subsets at concentrations of 2.5μM, 3μM, 3.5μM, 4μM, 4.5μM, and 5μM. The inhibitory effect increased significantly with increasing concentration. IFN-γ production was also significantly inhibited.

[0119] Table 1

[0120] Example 2: In vitro inhibition of differentiation of CD8+ T cells into Tc17 cells by CKBA compounds

[0121] 8-10 week old C57BL / 6 mice were selected and erythrocytes were lysed with erythrocyte lysis buffer to obtain spleen single cell suspension. Immediately immature CD8+ T cells were isolated using the mouse immature CD8+ T cell magnetic bead enrichment kit. + T cells were seeded at 1.0 x 105 cells per well in a 96-well plate and differentiated into IL-17A-producing effector cells (referred to as Tc17 cells) under induction with anti-CD3, anti-CD28, TGF-β, IL-6, IL-23, IL-1β, and anti-IFN-γ. CKBA compounds were added in a gradient of concentrations at a total volume of 200 μl per well. Control groups received corresponding concentrations of DMSO, while blank controls received only 200 μl of culture medium. Three replicates were set for each group.

[0122] After culturing in a cell culture incubator (37° C., 5% CO 2 ) for 72 hours, the proportion of Tc17 cells was detected by flow cytometry.

[0123] As shown in Figures 2A-C and Table 2, CKBA had no significant inhibitory effect on the differentiation of Tc17 cell subsets at concentrations of 0.5 and 1 μM. Compared to the DMSO control group, CKBA significantly inhibited the differentiation of Tc17 cell subsets at concentrations of 1.5, 2, 2.5, 3, 4, and 5 μM. This significantly inhibited IL-17A production.

[0124] Table 2

[0125] Example 3. Preparation of ointments and gels containing CKBA

[0126] The inventors unexpectedly discovered during their research that although CKBA can be mixed with different adjuvants to prepare different external dosage forms, the effects of different adjuvants vary significantly. A properly formulated ointment can significantly promote the effective absorption of CKBA, thereby helping CKBA to achieve better therapeutic effects.

[0127] A certain amount of CKBA compound was taken and prepared into 15 g of ointment according to the formula in Table 3.

[0128] Table 3

[0129] White vaseline manufacturer: Nanchang Baiyun Pharmaceutical Co., Ltd.; product batch number: 20221110.

[0130] Light liquid paraffin manufacturer: Nanchang Baiyun Pharmaceutical Co., Ltd.; product batch number: 20210603.

[0131] Meanwhile, a certain amount of CKBA compound was taken to prepare 15 g of gel according to the formula in Table 4.

[0132] Table 4

[0133] Example 4: Experiment on the treatment of vitiligo in mice with CKBA ointment

[0134] Twelve 9-week-old C57BL / 6 mice were injected with skin melanoma B16F10 cells into the lower right side of their backs. Twelve days later, the melanoma was surgically removed. Following 30 days of observation, animals whose hair in the surgical area turned white were selected as vitiligo models.

[0135] On the 30th day after surgery, 9 mice with vitiligo were selected and divided into 3 groups: a blank ointment (ointment prepared according to Table 3 but without CKBA), a 0.5% CKBA ointment treatment group, and a 1.0% CKBA ointment treatment group, with 3 mice in each group. The affected area was identified, photographed, and the hair was shaved. Then, the control ointment or CKBA ointment was applied at 15 mg / cm 2 , once a day for 4 consecutive weeks. On the last day, take photos to record the skin and hair color of the drug-administered site, then kill the mice by cervical dislocation, cut the skin of the affected site, embed the tissue in paraffin, and slice it, and histochemically stain it to detect CD8 + T cells.

[0136] The disease phenotype (the extent of whitening of the back hair and tail) of the animal model was observed. As shown in Figure 3, after 28 days of treatment, the white area in the Vehicle group increased, indicating worsening of the disease. In the 0.5% CKBA ointment group, the extent of whitening of the back hair and tail was significantly reduced after 28 days of treatment (*P < 0.05). In the 1% CKBA ointment group, the extent of whitening of the back hair and tail was greatly reduced after 28 days of treatment (**P < 0.01). A very significant disease-suppressing effect was observed in the 0.5% CKBA ointment group, and the degree of disease improvement in the 1% CKBA ointment group was superior to that in the 0.5% CKBA ointment group.

[0137] Detection of animal skin infiltrating CD8 + The results of T cell infiltration are shown in Figure 4. It can be seen that after 28 days of treatment, both the 0.5% CKBA ointment group (**P < 0.01) and the 1% CKBA ointment group (**P < 0.01) showed a significant increase in CD8 T cell infiltration. + The T cell content was greatly reduced, and the effect was more significant in the 1% CKBA ointment group (**P<0.01).

[0138] The above results show that CKBA ointment can effectively improve the phenotype of vitiligo, and its therapeutic effect on vitiligo is surprising.

[0139] Example 5: Comparison of transdermal properties of CKBA preparations

[0140] In this example, the in vitro percutaneous permeation characteristics of different types of CKBA preparations (gel or ointment) (Table 5) were analyzed to investigate the transdermal behavior and skin retention of CKBA when mixed with different excipients.

[0141] Table 5. Samples and controls

[0142] In vitro permeation tests of 0.5% and 1.0% gels and ointments were conducted as follows:

[0143] 1. Source and processing of ex vivo skin

[0144] The ex vivo skin of the abdomen and back of Bama miniature pigs (half a month old, 1-1.5 kg) was provided by Linxi County Jingde Agricultural Products Sales Co., Ltd. and stored in a -20°C refrigerator until use.

[0145] Before use, the skin was thawed in normal saline at room temperature. After checking the integrity of the skin, the surface moisture of the skin was absorbed with absorbent paper. The skin was cut along the outer edge of the supply pool and placed in normal saline for later use.

[0146] 2. Transdermal study design and methods

[0147] The in vitro permeation test is designed to simulate the skin penetration process of topical drugs under physiological conditions to reflect the quality of topical preparations and the effectiveness of clinical treatment. The present invention uses the Franz diffusion cell method to select pig back skin for in vitro permeation test of CKBA gel and ointment.

[0148] Experimental operation control: The test preparation was prepared in 6 parallel portions.

[0149] 3. Confirmation of in vitro transdermal analysis method for CKBA gel and ointment

[0150] With reference to the two content methods, we tried them separately, selected the better method, and made appropriate adjustments to serve as the chromatographic conditions for in vitro transdermal detection. The details are shown in Table 6.

[0151] Table 6. Comparison of CKBA content analysis methods

[0152] Both Method 1 and Method 2 blanks showed no interference and both produced normal peaks. Comparing the two methods, Method 1 had a shorter run time and better tailing than Method 2, so this method will be used in subsequent transdermal testing of CKBA gel and ointment samples.

[0153] 4. Transdermal test

[0154] (1) Sample preparation

[0155] Mobile phase A: 0.1% phosphoric acid solution, add 2 ml of phosphoric acid to 2000 ml of pure water, mix well and degas by ultrasonication.

[0156] Mobile phase B: acetonitrile.

[0157] Diluent: 90% methanol solution, measure 900ml of methanol and 100ml of pure water, mix well.

[0158] pH 7.4 PBS buffer: Weigh 3.4075 g of potassium dihydrogen phosphate and 0.79419 g of sodium hydroxide into a 500 ml volumetric flask, add water to the volume and shake well.

[0159] Receiving solution: pH 7.4 PBS buffer containing 40% PEG 400: Measure 157.5 ml of PEG 400 into a 500 ml volumetric flask, dilute to the mark with pH 7.4 PBS buffer, and shake well.

[0160] Eluate: Same as diluent.

[0161] Leachate: Same as elution.

[0162] Reference solution: Accurately weigh 5.029 mg of SCR-6477 reference substance into a 100 ml volumetric flask. Add an appropriate amount of diluent and sonicate to dissolve. Dilute to the mark with diluent and shake well. Label this solution as AS-STD #1. Prepare AS-STD #2 solution in the same manner, weighing 5.019 mg.

[0163] (2) Drug application and sampling

[0164] The transdermal test was performed using a Franz diffusion cell (instrument brand: LOGAN) with a diameter of 1.77 cm and a receiving cell volume of 5 ml. The receiving solution was a pH 7.4 PBS buffer solution containing 40% PEG400.

[0165] Obtain abdominal skin from a miniature pig, clean it, rinse it with saline, and blot it dry with filter paper. Once the transepidermal water loss (TEWL) value is acceptable (<15.0), place it under the donor cavity ring. Apply an appropriate amount of CKBA gel or ointment evenly to the stratum corneum (approximately 30 mg). Mount the skin with the sample on a diffusion cell with the stratum corneum facing up and the dermis facing down. Fill the dissolution cup with degassed receiving solution and place it in a constant-temperature water bath at 32 ± 1°C. Start a magnetic stirrer at 350 rpm and remove 4 ml of receiving solution every 12 hours. (Note: When measuring transepidermal water loss, the ambient temperature should be 20 to 25°C and the humidity should be 30% to 50% RH (non-condensing). Before mounting the skin, turn on the instrument and allow the receiving solution in the receiving chamber to equilibrate to 32°C.)

[0166] (3) Collection and extraction of remaining samples

[0167] First, after 12 hours of receiving solution sampling, remove the skin from the transdermal diffusion cell and inspect the skin surface for visible sample. Wipe the skin surface clean with two cotton swabs and place the wiped swabs in a 15ml centrifuge tube. Rinse the wiped pigskin surface with 5ml of eluate and place the rinsed receiving solution in the same 15ml centrifuge tube. Finally, wipe the remaining eluate on the pigskin surface with another cotton swab and place it in the same 15ml centrifuge tube.

[0168] Secondly, the matrix in the centrifuge tube was dispersed by vortexing with a vortexer, ultrasonicated for 10 minutes, placed in a constant temperature shaker to control the temperature at 32°C, shaken for 4 hours, and then centrifuged at 12000 rpm for 5 minutes to obtain the supernatant.

[0169] (4) In vitro skin retention detection

[0170] Cut the cleaned skin into pieces, add 5 ml of the extract, place it in a constant temperature shaker controlled at 32°C, shake it for 4 hours, then centrifuge it at 12000 rpm for 5 minutes, and take the supernatant.

[0171] (5) Calculation formula

[0172] a. Cumulative permeation Q

[0173] The cumulative release amount per unit area at time t is calculated as follows: Q = (Cn·V + ∑Ci·V) / S

[0174] Q is the cumulative permeation amount per unit area in time t (ng·cm-2), V is the volume of the solution in the receiving cell, Cn is the measured concentration of the nth sample, Ci is the measured concentration of the n-1th sample, and S is the effective permeation area.

[0175] b. Surface sample remaining amount W

[0176] The remaining amount W of the active ingredient in the gel on the skin surface is calculated according to the following formula: W = Cs·Vs

[0177] W is the remaining amount of active ingredient in the ointment on the skin surface (ng), Cs is the measured concentration of the active ingredient in the ointment on the skin surface, and Vs is the volume of the eluate.

[0178] c. Skin retention amount A

[0179] The drug retention amount A in the skin is calculated according to the following formula: A=V'Ct

[0180] A is the drug content per unit mass of skin (ng·g-1), Ct is the concentration measured after skin sample treatment at time t, and V' is the volume of the diluted skin after extraction.

[0181] (6) Experimental results

[0182] The results of the transdermal experiment are shown in Table 7 (statistically average values ​​of multiple batches and multiple animals).

[0183] Table 7. Transdermal test data

[0184] in conclusion

[0185] A higher skin retention indicates a sample with approximately ideal transdermal efficacy. Skin retention (μg): 1.0% CKBA ointment > 0.5% CKBA ointment > 1.0% CKBA gel > 0.5% CKBA gel. Surprisingly, the ointment formulation exhibited significantly better transdermal efficacy than the gel. No major component was detected in the receiving cell for any of the four sample batches.

[0186] The above-described embodiments merely represent several implementation methods of the present invention, and their descriptions are relatively specific and detailed, but they should not be construed as limiting the scope of the present invention. It should be noted that a person skilled in the art may make several modifications and improvements without departing from the scope of the present invention, and these modifications and improvements fall within the scope of protection of the present invention. Therefore, the scope of protection of the present invention shall be based on the appended claims. At the same time, all documents mentioned in this application are cited as references in this application, just as if each document was cited as a reference individually.

Claims

1. Use of the compound represented by formula (I) or its isomer, solvate or precursor, or pharmaceutically acceptable salts thereof, for preparing a pharmaceutical composition for alleviating or treating vitiligo; in, R is independently selected from the group consisting of hydrogen, hydroxy, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, halogen.

2. The use according to claim 1, It is characterized in that The pharmaceutical composition containing the compound represented by formula (I) is an external dosage form, including ointments, gels, foams, sprays, powders or creams.

3. The use according to claim 2, It is characterized in that The pharmaceutical composition is an ointment preparation, comprising: a compound represented by formula (I); and: The auxiliary agent 1 is selected from one or more of white vaseline, paraffin, lanolin, microcrystalline wax, beeswax, spermaceti, ozokerite, glyceryl stearate, stearic acid or cholesterol; preferably, the paraffin is light liquid paraffin; preferably, the auxiliary agent 1 is white vaseline and light liquid paraffin; Auxiliary agent 2 is selected from: one or more of isopropyl myristate, azone or N-methylpyrrolidone; preferably, the auxiliary agent 2 is isopropyl myristate; and The auxiliary agent 3 is selected from one or more of vitamin E, butylated hydroxytoluene, butylated hydroxyanisole, tocopherol, propyl gallate or tert-butylhydroquinone; preferably, the auxiliary agent 3 is vitamin E.

4. The use according to claim 1, It is characterized in that Described vitiligo is: CD8 + Vitiligo caused by differentiation of T cells into Tc1 cell subsets; and / or CD8 + Vitiligo is caused by T cell differentiation into Tc17 cell subset.

5. A pharmaceutical composition for alleviating or treating vitiligo, include: Compound represented by formula (I): wherein R is independently selected from the group consisting of hydrogen, hydroxy, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, halogen; and: The auxiliary agent 1 is selected from one or more of white vaseline, paraffin, lanolin, microcrystalline wax, beeswax, spermaceti, ozokerite, glyceryl stearate, stearic acid or cholesterol; preferably, the paraffin is light liquid paraffin; preferably, the auxiliary agent 1 is white vaseline and light liquid paraffin; Auxiliary agent 2 is selected from: one or more of isopropyl myristate, azone or N-methylpyrrolidone; preferably, the auxiliary agent 2 is isopropyl myristate; and The auxiliary agent 3 is selected from one or more of vitamin E, butylated hydroxytoluene, butylated hydroxyanisole, tocopherol, propyl gallate or tert-butylhydroquinone; preferably, the auxiliary agent 3 is vitamin E.

6. The use according to claim 3 or the pharmaceutical composition for alleviating or treating vitiligo according to claim 5, It is characterized in that The pharmaceutical composition comprises: a compound represented by formula (I), white vaseline, light liquid paraffin, isopropyl myristate and vitamin E, in parts by weight: The compound represented by formula (I): 25-250, preferably 50-200, such as 65, 75, 90, 120, 150 or 180 parts by weight; White vaseline: 9000-18000, preferably 10000-16500, such as 12000, 13347, 13422 or 15000 parts by weight; Light liquid paraffin: 400-1200, preferably 550-1000, such as 600, 650, 750, 800 or 900 parts by weight; Isopropyl myristate: 400-1200, preferably 550-1000, such as 600, 650, 750, 800 or 900 parts by weight; Vitamin E: 1.5-5, preferably 2-4.5, such as 2.5, 3, 4 parts by weight.

7. Use of the compound represented by formula (I) or its isomer, solvate or precursor, or a pharmaceutically acceptable salt thereof, for preparing a method for inhibiting CD8 + Compositions for T cell differentiation; in, R is independently selected from the group consisting of hydrogen, hydroxy, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, halogen; Preferably, the inhibition of CD8 + T cell differentiation: suppressor CD8 + Differentiation of T cells into Tc1; and / or, inhibition of CD8 + Differentiation of T cells into Tc17.

8. A method to inhibit CD8 + T cell differentiation method, It is characterized in that The method comprises: treating CD8 with a compound represented by formula (I) or an isomer, solvate or precursor thereof, or a pharmaceutically acceptable salt thereof; + T cells, thereby inhibiting CD8 + Differentiation of T cells; Preferably, the inhibition of CD8 + T cell differentiation: suppressor CD8 + T cells differentiate into Tc1 subset; and / or, inhibit CD8 + T cells differentiate into the Tc17 subset.

9. The method according to claim 8, It is characterized in that The compound represented by formula (I) or its isomer, solvate or precursor, or their pharmaceutically acceptable salt is in CD8 + The concentration in T cell culture is 1-100uM; preferably 2-80uM.

10. A method for alleviating or treating vitiligo, It is characterized in that The method comprises: administering an effective amount of the pharmaceutical composition of claim 5 or 6 to a subject in need of treatment.

Citation Information

Patent Citations

  • Pentacyclic triterpene structure modified compound as well as preparation method and application thereof

    CN104672293A

  • Pentacyclic triterpenes compound with ACC1 protein regulation effect and use of pentacyclic triterpenes compound

    CN106674323A

  • NOVEL ANALOGS OF 3-O-ACETYL-11-KETO-beta-BOSWELLIC ACID

    WO2005123649A1

  • A pentacyclic triterpenoid compound with modified structure and preparation method and use thereof

    WO2015078321A1

  • Pentacyclic triterpenoid crystal and preparation method therefor

    WO2022228352A1